Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Halofuginone in HIV-Related Kaposi's Sarcoma
NCT00064142Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2003
- Primary completion
- Dec 2006
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of halofuginone in Kaposi sarcoma (KS), sponsored by National Cancer Institute. Started May 2003; status: completed.
02
Drugs
halofuginone
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT00064142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00064142.